My NCBI | Sign In
RSS Settings
  • Search: Alleva DG[au]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 27

    1.

    Experimental autoimmune encephalomyelitis develops in CC chemokine receptor 7-deficient mice with altered T-cell responses.

    Pahuja A, Maki RA, Hevezi PA, Chen A, Verge GM, Lechner SM, Roth RB, Zlotnik A, Alleva DG.

    Scand J Immunol. 2006 Oct;64(4):361-9.PMID: 16970675 [PubMed - indexed for MEDLINE]Related articles

    2.

    Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope.

    Alleva DG, Maki RA, Putnam AL, Robinson JM, Kipnes MS, Dandona P, Marks JB, Simmons DL, Greenbaum CJ, Jimenez RG, Conlon PJ, Gottlieb PA.

    Scand J Immunol. 2006 Jan;63(1):59-69.PMID: 16398702 [PubMed - indexed for MEDLINE]Related articles

    3.

    A high-throughput chemotaxis assay for pharmacological characterization of chemokine receptors: Utilization of U937 monocytic cells.

    Ott TR, Pahuja A, Lio FM, Mistry MS, Gross M, Hudson SC, Wade WS, Simpson PB, Struthers RS, Alleva DG.

    J Pharmacol Toxicol Methods. 2005 Mar-Apr;51(2):105-14. Epub 2004 Nov 5.PMID: 15767203 [PubMed - indexed for MEDLINE]Related articles

    4.

    Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist.

    Heise CE, Pahuja A, Hudson SC, Mistry MS, Putnam AL, Gross MM, Gottlieb PA, Wade WS, Kiankarimi M, Schwarz D, Crowe P, Zlotnik A, Alleva DG.

    J Pharmacol Exp Ther. 2005 Jun;313(3):1263-71. Epub 2005 Mar 10.PMID: 15761110 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Identification of CC chemokine receptor 7 residues important for receptor activation.

    Ott TR, Pahuja A, Nickolls SA, Alleva DG, Struthers RS.

    J Biol Chem. 2004 Oct 8;279(41):42383-92. Epub 2004 Jul 28.PMID: 15284247 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Cuttine edge: diabetes-associated quantitative trait locus, Idd4, is responsible for the IL-12p40 overexpression defect in nonobese diabetic (NOD) mice.

    Simpson PB, Mistry MS, Maki RA, Yang W, Schwarz DA, Johnson EB, Lio FM, Alleva DG.

    J Immunol. 2003 Oct 1;171(7):3333-7.PMID: 14500624 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Persistence of immune responses to altered and native myelin antigens in patients with multiple sclerosis treated with altered peptide ligand.

    Kim HJ, Antel JP, Duquette P, Alleva DG, Conlon PJ, Bar-Or A.

    Clin Immunol. 2002 Aug;104(2):105-14.PMID: 12165271 [PubMed - indexed for MEDLINE]Related articles

    8.

    Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide.

    Alleva DG, Gaur A, Jin L, Wegmann D, Gottlieb PA, Pahuja A, Johnson EB, Motheral T, Putnam A, Crowe PD, Ling N, Boehme SA, Conlon PJ.

    Diabetes. 2002 Jul;51(7):2126-34.PMID: 12086942 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Regulation of murine macrophage proinflammatory and anti-inflammatory cytokines by ligands for peroxisome proliferator-activated receptor-gamma: counter-regulatory activity by IFN-gamma.

    Alleva DG, Johnson EB, Lio FM, Boehme SA, Conlon PJ, Crowe PD.

    J Leukoc Biol. 2002 Apr;71(4):677-85.PMID: 11927655 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    SJL and NOD macrophages are uniquely characterized by genetically programmed, elevated expression of the IL-12(p40) gene, suggesting a conserved pathway for the induction of organ-specific autoimmunity.

    Alleva DG, Johnson EB, Wilson J, Beller DI, Conlon PJ.

    J Leukoc Biol. 2001 Mar;69(3):440-8.PMID: 11261792 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin.

    Alleva DG, Crowe PD, Jin L, Kwok WW, Ling N, Gottschalk M, Conlon PJ, Gottlieb PA, Putnam AL, Gaur A.

    J Clin Invest. 2001 Jan;107(2):173-80.PMID: 11160133 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Aberrant macrophage cytokine production is a conserved feature among autoimmune-prone mouse strains: elevated interleukin (IL)-12 and an imbalance in tumor necrosis factor-alpha and IL-10 define a unique cytokine profile in macrophages from young nonobese diabetic mice.

    Alleva DG, Pavlovich RP, Grant C, Kaser SB, Beller DI.

    Diabetes. 2000 Jul;49(7):1106-15.PMID: 10909966 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Intrinsic defects in macrophage IL-12 production associated with immune dysfunction in the MRL/++ and New Zealand Black/White F1 lupus-prone mice and the Leishmania major-susceptible BALB/c strain.

    Alleva DG, Kaser SB, Beller DI.

    J Immunol. 1998 Dec 15;161(12):6878-84.PMID: 9862720 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Tumor-induced immune dysfunction: the macrophage connection.

    Elgert KD, Alleva DG, Mullins DW.

    J Leukoc Biol. 1998 Sep;64(3):275-90. Review.PMID: 9738653 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Aberrant cytokine expression and autocrine regulation characterize macrophages from young MRL+/+ and NZB/W F1 lupus-prone mice.

    Alleva DG, Kaser SB, Beller DI.

    J Immunol. 1997 Dec 1;159(11):5610-9.PMID: 9548504 [PubMed - indexed for MEDLINE]Related articles

    16.

    IL-15 functions as a potent autocrine regulator of macrophage proinflammatory cytokine production: evidence for differential receptor subunit utilization associated with stimulation or inhibition.

    Alleva DG, Kaser SB, Monroy MA, Fenton MJ, Beller DI.

    J Immunol. 1997 Sep 15;159(6):2941-51.PMID: 9300718 [PubMed - indexed for MEDLINE]Related articles

    17.

    Taxol, a microtubule-stabilizing antineoplastic agent, differentially regulates normal and tumor-bearing host macrophage nitric oxide production.

    Mullins DW, Alleva DG, Burger CJ, Elgert KD.

    Immunopharmacology. 1997 Aug;37(1):63-73.PMID: 9285245 [PubMed - indexed for MEDLINE]Related articles

    18.

    Induction of macrophage suppressor activity by fibrosarcoma-derived transforming growth factor-beta 1: contrasting effects on resting and activated macrophages.

    Alleva DG, Walker TM, Elgert KD.

    J Leukoc Biol. 1995 Jun;57(6):919-28.PMID: 7790775 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Promotion of macrophage-stimulated autoreactive T cell proliferation by interleukin-10: counteraction of macrophage suppressor activity during tumor growth.

    Alleva DG, Elgert KD.

    Immunobiology. 1995 Feb;192(3-4):155-71.PMID: 7782092 [PubMed - indexed for MEDLINE]Related articles

    20.

    Macrophage priming and activation during fibrosarcoma growth: expression of c-myb, c-myc, c-fos, and c-fms.

    Alleva DG, Askew D, Burger CJ, Elgert KD.

    Immunol Invest. 1994 Nov;23(6-7):457-72.PMID: 7851963 [PubMed - indexed for MEDLINE]Related articles

    21.

    Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2.

    Alleva DG, Burger CJ, Elgert KD.

    J Immunol. 1994 Aug 15;153(4):1674-86.PMID: 8046239 [PubMed - indexed for MEDLINE]Related articles

    22.

    Tumour growth causes suppression of autoreactive T-cell proliferation by disrupting macrophage responsiveness to interferon-gamma.

    Alleva DG, Burger CJ, Elgert KD.

    Scand J Immunol. 1994 Jan;39(1):31-8.PMID: 7904773 [PubMed - indexed for MEDLINE]Related articles

    23.

    Increased sensitivity of tumor-bearing host macrophages to interleukin-10: a counter-balancing action to macrophage-mediated suppression.

    Alleva DG, Burger CJ, Elgert KD.

    Oncol Res. 1994;6(4-5):219-28.PMID: 7841545 [PubMed - indexed for MEDLINE]Related articles

    24.

    Fibrosarcoma-induced increase in macrophage tumor necrosis factor alpha synthesis suppresses T cell responses.

    Alleva DG, Askew D, Burger CJ, Elgert KD.

    J Leukoc Biol. 1993 Aug;54(2):152-60.PMID: 8360594 [PubMed - indexed for MEDLINE]Related articlesFree article

    25.

    Tumor-induced macrophage tumor necrosis factor-alpha production suppresses autoreactive T cell proliferation.

    Alleva DG, Burger CJ, Elgert KD.

    Immunobiology. 1993 Aug;188(4-5):430-45.PMID: 8244447 [PubMed - indexed for MEDLINE]Related articles

    26.

    Tumor growth increases Ia- macrophage synthesis of tumor necrosis factor-alpha and prostaglandin E2: changes in macrophage suppressor activity.

    Alleva DG, Burger CJ, Elgert KD.

    J Leukoc Biol. 1993 May;53(5):550-8.PMID: 8388910 [PubMed - indexed for MEDLINE]Related articlesFree article

    27.

    Interferon-gamma reduces tumor-induced Ia- macrophage-mediated suppression: role of prostaglandin E2, Ia, and tumor necrosis factor-alpha.

    Alleva DG, Burger CJ, Elgert KD.

    Immunopharmacology. 1993 May-Jun;25(3):215-27.PMID: 8354638 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    1 free full-text article in PubMed Central

    Find related data

    Search details

    » See more...

    Recent activity